Since IL‐1β drives NLRP3 gene induction, anti‐IL‐1β therapies in humans can stop a positive feedback loop that maintains most of the CAPS patients' inflammatory symptoms. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.